Schedule 13D ownership disclosure

Armata Pharmaceuticals, Inc.

Security class unavailable · CUSIP: 04216R102

Event date: 2022-03-15

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
57,345,794
Percent of class
74.9300%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-22-033706
Form type
SC 13D
Filer
Entasis Therapeutics Holdings Inc.
CIK
CIK 1724344
Filed
Mar 15, 2022
Reporting period
Mar 15, 2022
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub